CordenPharma is pleased to announce the completion of a new highly potent API laboratory in its Boulder, Colorado facility.
CordenPharma Colorado has extensive experience and capabilities in the development and manufacturing of highly potent APIs from clinical to commercial scale. “Our new laboratory in Colorado is part of a development capacity expansion to address the strong market demand. This additional capacity benefits customers by expediting the onboarding of new projects,” comments Jason Bertola, Director of CordenPharma’s Global Highly Potent & Oncology Platform.
The new laboratory is capable of handling highly potent compounds with an OEL as low as 1ng/m3, and is already available to customers.
CordenPharma, the global pharmaceutical service & manufacturing platform of International Chemical Investors Group (ICIG), is a full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products, and associated Packaging Services. Through a growing network of cGMP facilities across Europe and the US organized under four Technology Platforms – Peptides, Lipids & Carbohydrates, Injectables, Highly Potent & Oncology, and Small Molecules – CordenPharma experts translate complex processes and projects at any stage of development into high-value products.
CordenPharma Media Contacts
Europe & Asia